Page 1,182«..1020..1,1811,1821,1831,184..1,1901,200..»

Category Archives: Transhuman News

Atopic Dermatitis Drugs Market projected to expand at a CAGR of ~27% from 2019 to 2027 – PRnews Leader

Posted: October 20, 2020 at 6:19 pm

The globalatopic dermatitis drugs marketis likely to expand substantially in the years to come owing to progress made in various drug classes. The market is estimated to rise at a double-digit growth rate of 27% CAGR, over the timeframe of forecast, 2019 to 2027. The global atopic dermatitis drugs market is anticipated to acquire prominence reaching value of US$ 19.6 Bn through 2027.

Atopic dermatitis (AD) refers to a common type of eczema, which affects a large percentage of the population across the globe. Atopic dermatitis, though, can happen at any point of time in ones life, but it generally affects children and infants. Atopic dermatitis, however, lessen its impact with age. With increased prevalence of atopic dermatitis is likely to back growth of the global atopic dermatitis drugs market over timeframe of assessment.

Bristol-Myers Squibb Company, Anacor Pharmaceutical Inc., Regeneron Pharmaceuticals, Inc., Novartis International AG, Allergan Plc., and Astellas Pharma, Inc. are some of the renowned companies found in the global atopic dermatitis drugs market.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73639

Increased Awareness about Various Treatment Options to Boost North America Market

The global atopic dermatitis drugs market has been segmented into the major geographies of North America, Europe, Asia Pacific, Middle East and Africa, and Latin Africa. Region-based segmentations offer a detailed view of the market in various parts of the world.

In the global atopic dermatitis drugs market, North America is likely to offer high growth opportunity over the assessment tenure. Growth of the North America atopic dermatitis drugs market is ascribed to the awareness about available treatment options amongst the people. Canada and the U.S. is estimated to spearhead the growth of the regional market owing to early adoption of new medications, increased collaboration between pharmaceutical companies, improved healthcare infrastructure, and better reimbursement policies. All such factors combines add to the growth of the global atopic dermatitis drugs market during the forecast timeframe.

Request for Analysis of COVID19 Impact on Atopic Dermatitis Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=73639

Increased Prevalence of Atopic Dermatitis to Spell Growth for the Market

The global atopic dermatitis drugs market is expected to be primarily driven by the rising occurrences of atopic dermatitis drugs all over the globe. Allergy of any kind plays an important role in the life of a person with atopic dermatitis. This condition generally flares up when a person with atopic dermatitis disease is around substances that can cause allergic reactions. Mostly affecting children and infants, atopic dermatitis, is estimated to account for around 10 to 20% of those suffering from eczema, according to the data of American College of Allergy, Asthma & Immunology.

The global atopic dermatitis drugs market is forecasted to ride high with the introduction of new treatment methods and biologics and improvement in the diagnostics technology. In addition, replacement of second-line and primary therapies along with premium-priced drugs is likely to offer ample scope of growth of the global atopic dermatitis drugs market.

The information shared in this review is based on a TMR report, bearing the title, Atopic dermatitis drugs market (Drug Class Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, and Biologics; Distribution Channel Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2019 to 2027

Buy Atopic Dermatitis Drugs Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=73639&ltype=S

The globalAtopic Dermatitis Drugs Marketis segmented based on:

Drug Class

Distribution Channel

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Excerpt from:
Atopic Dermatitis Drugs Market projected to expand at a CAGR of ~27% from 2019 to 2027 - PRnews Leader

Posted in Eczema | Comments Off on Atopic Dermatitis Drugs Market projected to expand at a CAGR of ~27% from 2019 to 2027 – PRnews Leader

Virtually Supported Home Peanut Introduction is Viable Option – MD Magazine

Posted: at 6:19 pm

With the impact of the coronavirus disease 2019 (COVID-19) lockdown measures continuing to be felt across the US, access to healthcare resources for the management of allergic disease are still limited.And although in-person services may be offered by clinics, concern or fear over exposure to the virus can certainly hinder patient use of such services.

And yet, certain allergic conditions, such as peanut allergies in high-risk infants, require expedited assessments and active management.

A report written by Douglas Mack, MD, Assistant Clinical Professor, Pediatrics, McMaster University, and colleagues detailed the first known use of a virtually supported home peanut introduction in infant patients at risk of developing peanut allergy. The program was conducted earlier this year in April.

Prior to initiation of the virtual program, infants were screened for eligibility in a private-practice allergist setting using the telehealth platform Doxy.me.

Patients were eligible if they had physician-diagnosed severe eczema, physician diagnosed egg allergy, SPT3 mm or 0.35 kU/L without prior ingestion, perceived high-risk by caregiver, or had caregiver anxiety to introduce a particular food.

Excluded from the study were patients with a history of systemic IgE-mediated reaction to the food in questions; had certain underlying conditions, such as uncontrolled asthma, cardiac conditions, respiratory conditions; or used a beta-blocker.

During this first consultation, parents or guardians were informed about the risks and benefits of either prolonging peanut avoidance until the first in-person visit or participating in the virtually-support food introduction process.

If they chose to proceed with the program, then consent was obtained, and they were prescribed an epinephrine autoinjector and rupatadine.

In the next visit with the physicians, caregivers were then informed about the process, possible symptoms, and treatment.

Then they were instructed to prepare peanut putter by dissolving 2 teaspoons of it in 2-3 teaspoons of hot water, then letting it cool.

Caregivers then gradually introduced 2 g of peanut butter every 10-15 minutes over 45 minutes 1 hour.

If any symptoms occurred, the guardian used the telehealth program to contact the physicians for further assessment. If the physicians were unable to be reached, then caregivers were instructed to administer epinephrine and/or antihistamine or contact emergency medical services.

However, if no symptoms occurred, then the physicians would advise ingestion of the food of similar or increased amounts 2-3 per week.

Mack and colleagues referenced recent clinical guidelines that provide a framework for at-home management of anaphylaxis. They suggest that using these guidelines would be necessary in the event of such reactions during the virtually supported food introduction.

Nonetheless, they noted that no reactions were reported during the food introduction process, which they considered to be consistent with the current evidence that anaphylaxis is rare and non-threatening with first ingestion in infancy. Thus, they emphasized that mild reactions can generally be managed with antihistamine and/or observation.

Even before COVID-19, lack of allergist resources presented significant barriers to the introduction of peanut to at-risk patients where there was hesitance, they wrote.

During COVID-19, the need to provide alternative forms of care is heightened. Virtually supported introduction may represent a future option after COVID-19 to improve access for patients who live in remote areas, or otherwise have limited access to allergists, or for clinicians with overburdened clinics.

They acknowledged that the implementation of such a strategy requires formal evaluation of safety, cost-effectiveness, caregiver/physician acceptability, sustainability, and patient satisfaction.

The report, Virtually supported home peanut introduction during COVID-19 for at-risk infants, was published online in The Journal of Allergy and Clinical Immunology: In Practice.

Read more from the original source:
Virtually Supported Home Peanut Introduction is Viable Option - MD Magazine

Posted in Eczema | Comments Off on Virtually Supported Home Peanut Introduction is Viable Option – MD Magazine

Global Colloidal Oatmeal Skin Care Products Market Forecast Probabilities, Growth Expectations, Reve – PharmiWeb.com

Posted: at 6:19 pm

Pune, Maharashtra, October 14 2020 (Wiredrelease) Market.Biz :Colloidal Oatmeal Skin Care Products Market Overview

This comprehensive market research report offers of an in-depth outlook on the Global Colloidal Oatmeal Skin Care Products Market encompassing crucial factors such as the overall size of the global Colloidal Oatmeal Skin Care Products market, in both regional and country-wise terms, as well as market share values, an analysis of recent developments and potential opportunities, sales and competitive landscape analysis, expected product launches, technological innovations (both developed and those in-progress), revenue and trade regulation analysis, among other significantly detailed aspects of the global Colloidal Oatmeal Skin Care Products market, in 2020 and beyond.

The global Colloidal Oatmeal Skin Care Products market is anticipated to gain exponential industry growth over the given forecast period of 2020-2030, with a higher projected value, from estimated values in 2020, indexing a CAGRrate by the end of the aforementioned timeline.

Click Here To Get Free Sample PDF

Global Colloidal Oatmeal Skin Care Products Market segmentation:

Market segmentation of the Colloidal Oatmeal Skin Care Products industry is carried out on the basis of Type, Applications, as well as regions and countries. With respect to Type, segmentation is carried out under Medicinal Grade, Cosmetics Grade, and Others. And concerning the applications, segmentation Eczema Cream with Colloidal Oatmeal, Moisturizer with Colloidal Oatmeal, Cleanser with Colloidal Oatmeal, Others, In Colloidal Oatmeal Skin Care Products market, the Moisturizer with Colloidal Oatmeal holds an important share up to 33%, and the second large part is Cleanser with Colloidal Oatmeal;

Colloidal Oatmeal Skin Care Products Market Segments

Type

Medicinal Grade, Cosmetics Grade

Application

Eczema Cream with Colloidal Oatmeal, Moisturizer with Colloidal Oatmeal, Cleanser with Colloidal Oatmeal, Others, In Colloidal Oatmeal Skin Care Products market, the Moisturizer with Colloidal Oatmeal holds an important share of up to 33%, and the second large part is Cleanser with Colloidal Oatmeal

Regions and Countries Level Analysis:

An in-depth analysis of specified regions and their respective countries are carried out to ensure that the exact detailing of the Colloidal Oatmeal Skin Care ProductsBusiness footprint and its sales demographics are effectively captured with precision, to allow our users to utilize this data to the fullest of their abilities.

Any Query? Do Enquiry @ https://market.biz/report/global-colloidal-oatmeal-skin-care-products-market-gm/#inquiry

The report offers a brief evaluation of the growth and other detail of the Colloidal Oatmeal Skin Care Products Market in important countries (regions), including:

North America Europe Asia Pacific Latin America The Middle East and Africa

Competitive Landscape of the Colloidal Oatmeal Skin Care Productsindustry Share Analysis:

Our analysis of the Colloidal Oatmeal Skin Care Products markets competitive landscape will include market competition examination, by company, its respective overview, business description, product portfolio, key financials, etc. We also include market probability scenarios, a PEST analysis, Porter Five Forces analysis, supply-chain analysis, as well as market expansion strategies.

The major players covered in Colloidal Oatmeal Skin Care Products Market are:

Johnson & Johnson?AVEENO?, Croda, Lantmnnen?Avenacare?, Swedish Oat Fiber AB?Naturex SA?, Quaker Oats Company, Morning Foods, Grain Millers

BUY Colloidal Oatmeal Skin Care Products Market Research Report Here

Reasons to Get this Report:

In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and global Colloidal Oatmeal Skin Care Products market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of global Colloidal Oatmeal Skin Care Productsmarket; high-growth regions; and market drivers, restraints, and also market chances.

The analysis covers the global Colloidal Oatmeal Skin Care Products Business and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Colloidal Oatmeal Skin Care Products Industry across sections such as also application and representatives. Additionally, the analysis also has a comprehensive review of the crucial players on the global Colloidal Oatmeal Skin Care Products market together side their company profiles, SWOT analysis, latest advancements, and business plans.

Chapter 1:

This section will give you an insight into the global Colloidal Oatmeal Skin Care Products market as a whole, proceeding to lend a descriptive overview of this industry.

Chapter 2:

This section now delves further into the anatomy of the global Colloidal Oatmeal Skin Care Products market, detailing market segmentation with respective growth rates and revenue share comparisons.

Chapter 3-7:

The following chapters will comprise of a comprehensive analysis of the global Colloidal Oatmeal Skin Care Products markets segmentation with respect to the various regions and countries.

Check Out The Complete Toc Here: https://market.biz/report/global-colloidal-oatmeal-skin-care-products-market-gm/#toc

Contact Us:

Office Addresses: 420 Lexington Avenue Suite 300New York City, NY 10170, United StatesUSA/Canada Tel No: +1-857-2390696Email: inquiry@market.biz

This content has been published by Market.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

See the original post:
Global Colloidal Oatmeal Skin Care Products Market Forecast Probabilities, Growth Expectations, Reve - PharmiWeb.com

Posted in Eczema | Comments Off on Global Colloidal Oatmeal Skin Care Products Market Forecast Probabilities, Growth Expectations, Reve – PharmiWeb.com

Atopic Eczema Treatment Market Estimated to Experience a Hike in Growth by 2026 – Stock Market Vista

Posted: at 6:19 pm

Atopic Eczema Treatment market report provides a detailed insight into the global market landscape and has an in-detail evaluation of the key market prospects. Growth dynamics and leading trends and other essential market prospects have been assessed in order to give the clients an in-depth understanding of the Atopic Eczema Treatment market. The report has a detailed forecast up to 2026 and a historical overview of the Atopic Eczema Treatment market.

Key Market Players mentioned are:Leo PharmaVelite PharmaceuticalPfizerAnacor PharmaceuticalRegeneron PharmaceuticalsSanofi

The report details and accounts for important and essential factors crucial to mapping a successful business plan and crafting strategies to ensure a profitable growth curve for the Atopic Eczema Treatment Market. Clients can get a detailed assessment of aspects such as revenue, growth, trends, scope, opportunities, risks, etc. to create a much stronger and effective business canvas. Stakeholders as well as the new players in the Atopic Eczema Treatment market can utilize this report and maximize their revenue generation potential and secure dominance in the global Atopic Eczema Treatment Market.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/1361546?RINT

Description:

This report on the Atopic Eczema Treatment market can be a complete guide to navigate our clients through the Atopic Eczema Treatment market and aid you in accordance with all the essential data required to establish dominance or sustain dominance in the Atopic Eczema Treatment market. The analysts have prepared a detailed and descriptive account of the market in the given report.

Clients through this report can strategize an effective and essential business plan and create an extensive business model to sustain over a long period of time. The report utilizes most of the in demand analyses and has been equipped with the most up to date data to give a complete understanding of the Atopic Eczema Treatment market. Business development, opportunities, dynamics, and expansion all can be navigated through the use of this latest report on the Atopic Eczema Treatment market.

The report is assessed using analyses such as SWOT analysis, Porters Analysis, predictive analysis, mechanistic analysis, and other essential analyses which are crucial to a good market research report. The report is perfectly suitable for all kinds of work approaches and is customizable to ensure maximum efficiency in the workflow.

Atopic Eczema Treatment Market Type Coverage: OralTopicalParenteral

Atopic Eczema Treatment Market Application Coverage: Hospital PharmaciesRetail PharmaciesOnline Pharmacies

Market Segment by Regions and Nations included:

North America Country (United States, Canada)South AmericaAsia Country (China, Japan, India, Korea)Europe Country (Germany, UK, France, Italy)Other Country (Middle East, Africa, GLeo PharmaVelite PharmaceuticalPfizerAnacor PharmaceuticalRegeneron PharmaceuticalsSanofi

)

Competitive Analysis:

The report has up to date data required to gain an edge over the different competitors in the Atopic Eczema Treatment market. The report has discussed in detail the mergers and acquisitions currently in place in the Atopic Eczema Treatment market landscape. The report illustrates an extensive account of the competitive landscape of the global market. The report will help our clients to navigate and emerge among the frontrunners of the market and for the current key players they will be able to sustain their lead in the market for a longer duration through the use of this report.

Get the discounted price for this report @https://www.reportsintellect.com/discount-request/1361546?RINT

About Us:

Reports Intellect is your one-stop solution for everything related to market research and market intelligence. We understand the importance of market intelligence and its need in todays competitive world.

Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you.So whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact Us:

sales@reportsintellect.com Phone No: + 1-706-996-2486US Address: 225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Visit link:
Atopic Eczema Treatment Market Estimated to Experience a Hike in Growth by 2026 - Stock Market Vista

Posted in Eczema | Comments Off on Atopic Eczema Treatment Market Estimated to Experience a Hike in Growth by 2026 – Stock Market Vista

The protein Klotho could extend the life of the brain. Is that a good thing? – Massive Science

Posted: at 6:17 pm

Now's the time to live forever. Futurologists and transhumanists are poking themselves with what molecules they can, seeing what there is that might extend their lives or preserve their brains. One of the most intriguing molecules out there is called Klotho. Identified in 1997, it's named for the Fate of ancient Greek mythology who spun the thread the life. Mice that have a severely limited amount of Klotho in their body age rapidly and die prematurely. On the other hand, mice that carry more Klotho than normal live longer lives and appear to be resistant in some ways to aging.

Last April, an article appeared in the New York Times, titled "One Day There May Be a Drug to Turbocharge the Brain. Who Should Get it?" Massive contributor and neuroscientist Yewande Pearse and editor Dan Samorodnitsky sat down (in front of their computers) to talk about Klotho what it is, what it does, and whether prescribing a drug to supercharge the brain is a good idea.

Dan Samorodnitsky: Would it have to be prescribed by a doctor? Bought over the counter? Available at *chuckles to self* "Klotho shops"?

Yewande Pearse: This is a really interesting question because unlike a lot of other drugs, Klotho is a) a naturally occurring protein and b) has the potential to protect, treat and enhance the brain, therefore, the answer depends on the circumstances.

Mouse studies have revealed that Klotho plays an important role in the aging process. Mice with mutations in the Klotho gene have phenotypes which resemble different aspects of human aging, such as slowed growth, calcifying blood vessels, osteoporosis, and premature death. With respect to brain function, when mice with symptoms of age-related Alzheimer's disease are given Klotho, they are protected from cognitive decline. However, the exact biological function of Klotho and the way in which Klotho deficiency contributes to age-related diseases is not understood in mice, let alone humans.

Klotho has also has been shown to decrease with age in human blood serum samples, which may have something to do with cognitive decline in aging. Having said that, we all age, but we don't all develop Alzheimer's disease. Interestingly, people who carry a genetic variation of the Klotho gene that causes them to produce more Klotho, seem to not only be protected from Alzheimer's disease, but also perform better on cognitive tests like the Mini-Mental State Exam (MMSE)than people who produce average levels of Klotho.

Therefore, this becomes a question of dosage. To answer whether Klotho would have to be prescribed, we need to figure out the dose of Klotho required to prevent, treat, and enhance, and whether there are dose dependent risks. Perhaps a good starting point would be to calculate how much extra Klotho people with that gene variant produce compared to the average person versus how much less Klotho people who develop Alzheimer's disease have compared to those who do not of the same age.

It is also important to think about the structure and expression of Klotho when answering this question. Klotho is actually a transmembrane protein which means that it sits in the cell wall. Most of Klotho exists outside of the cell, but can be chopped off and released into the blood, urine, and cerebrospinal fluid. These different forms of Klotho all have different functions. Therefore, simply taking Klotho orally, is not as simple as it sounds, as it is unlikely that it will get it into its natural place in thebody, especially if we are trying to get it to the brain where it would have to cross the blood-brain-barrier, which prevents large molecules from passing through. To properly capture the full range of Klotho functions, we may be better off thinking about targeting the gene expression of Klotho itself something that may go beyond even a doctors prescription.

Multi-color whole brain image taken by fMRI

NIH via Flickr

But are naturally occurring levels of Klotho at the evolutionarily "correct" expression level?

Klotho is considered to be an aging-suppressor gene with multiple functions that protect organs. However, this protection doesn't last forever as Klotho declines with age.

To answer this question, we need to address a different question first: How and why do we age? There is no unified theory to explain the overall transformation taking place in the body during aging, but several theories, such as random mutation of genes, accumulation of damage by free radicals and the degeneration of functions like immunity are all valid on a local level. The reduction in Klotho as we age, for example, might fall into the last category, helping to explain dementia in the aging brain.

The "why?" is about trying to understand aging in terms of its necessity for survival. That sounds like a contradiction but is important when considering whether or not we should be taking Klotho as a drug. In 1889, August Weismann proposed that aging is a natural process of wearing out. If this is the case, then it is tempting to argue that there is no evolutionarily "correct" expression level of Klotho beyond child-bearing age. Klotho protects us for long enough to pass on our genes, after which point evolution has no reason to select for prolonged lifespan. This is why we don't all carry the "extra Klotho" genetic variant. However, the fact that better health care has granted us longer life regardless means that having higher levels of Klotho to maintain cognition is certainly preferable, and we could also argue that naturally occurring levels of Klotho are inadequate and should be augmented. Does that make sense?

It does make sense. Should we be concerned about, I don't know how to put it, over-correction? It feels like a moving target to nail down a dosage of Klotho that works well with any individual's natural expression of Klotho, natural variants, mutations, the three different variants of Klotho, just the overall difficulty of nailing down medications aimed at the nervous system.

Definitely, I think that caution is certainly needed given the fact that some studies have shown that one variant is actually associated with increased dementia and schizophrenia, suggesting that positive effects of Klotho on cognition may actually be limited by time, sex, and other factors. Having said that, all drugs, many of which have saved and improved lives, face the same challenge.

I think that Klotho research should focus on preventing the development of Alzheimers in people at risk first. In other words, trying to better understand Klotho as a potential biomarker, not just a treatment. There are no human studies to show what happens when Klotho is given to those who already have dementia, so early intervention is probably key. For the rest of us, research should focus on how our natural expression level of Klotho might be impacted by diet, exercise, etc., rather than heading straight down the pharmaceutical rout. For example, studies show that exercise, carbs, activated charcoal, probiotics and even statins can all increase the production of Klotho.

Is there evidence of disease from lack of Klotho in the body (maybe similar to imbalances occurring in some mental illnesses)?

The first clues about the function of Klotho came from mouse studies in which, the Klotho gene was deliberately mutated so that they didn't produce the normal level of Klotho. These mice had shorter life-spans and interestingly, showed a rapid decline in cognitive function, but only after a certain age. With mouse studies continuing to support the idea that Klotho expression levels correlate with both body (Klotho is made in the kidney too!) and brain function, there is now a lot of interest in Klotho as an indicator of health and disease.

A lack of Klotho in the body has been shown to correlate with a number of psychological conditions from chronic stress, which can lead to other psychiatric illnesses, and bipolar disorder. Lower levels of Klotho have also been associated with disease severity in multiple sclerosis and epilepsy. Generally, Klotho levels are lower in older people, but in Alzheimer's disease, patients, especially female patients, have even less Klotho.

A cross-section of a mouse cerebellum

NIH via Flickr

Also, and I'm sorry to keep harping on this, there's this quote from the original New York Times article that started this conversation:

"Some people carry a genetic variation that causes them to produce higher levels of Klotho than average in their bodies. Dr. Dubal and her colleagues identified a group of healthy old people with the variant and tested their cognition.

They scored better than people who make an average level of Klotho. Its not like they didnt undergo cognitive decline, said Dr. Dubal. Its just that they started off higher.

Maybe I'm just confused about the difference between Klotho making people "smarter" and people having "higher cognition" or something?

This is the part of the article that really jumped out at me. This is an important distinction. In this study, they found that differences in cognition as measured by IQ scores were only apparent after the age of 60. This means that these individuals experienced a delay in cognitive decline compared to people of the same age with the normal level of Klotho. Before 60, IQ scores were comparable but then after 60, people with lower levels of Klotho experienced a drop in IQ. Klotho is all about anti-aging, so we need to thinking about cognitive decline as a feature of aging and Klotho as an anti-aging protein. Assuming that we have the same IQ and we don't have the Klotho variant, if you were to start taking Klotho now (pretend they've cracked the issues above) and I didn't, I don't think you'd suddenly get smarter, I just think that when we got older, I'd start experiencing cognitive decline before you.

Do you worry about the number of apparent medical functions Klotho has ascribed to it? Increases overall brain function (but doesn't make you smarter), increases lifespan, and protects against a bunch of different, un-related diseases like Alzheimer's, Parkinson's, and MS? Seems like a lot of effects for one protein.

I am fascinated by the fact that Klotho has so many effects! It's a bit of a super protein. I am not surprised though because although all these effects seem disparate, they share common pathways upon which Klotho acts. For example, Kotho has antioxidant effects that are important for multiple functions both in the brain and the kidneys.

What I am worried about though is the fact that little is actually known about the function of Klotho and how aging suppression might work. I think we should be very careful about altering something that does indeed have so many actions and effects. Once Klotho is secreted, it enters the blood stream and goes everywhere, but by taking Klotho orally, I am not sure how can we ensure Klotho is going to the right places in the right quantities in a way that is effective and safe.

Do you worry about the ethics of taking Klotho? Taking it as a replacement drug, like if someone has low Klotho, seems fine, but beyond that? Should neuroscience researchers worry about that?

Are you asking me whether I think it's unethical to want to live longer and better? I'm tempted to go off on a tangent about our human endeavor to live forever and what that is doing to the environment. But, if we are going to live longer, is it wrong to want a better quality of life as measured by staying sharper into out 70s, 80s and 90s? I don't think that desire is unethical.

However, if we are talking about the ethics of taking an enhancement drug that not everyone has access to then my answer would lean more towards no but I'd say the same about food equity and a hundred other things that influence our health and well-being. I guess that answer is more personal. As a neuroscience researcher, my priority is safety and the ethics around that. If we can ensure that taking "extra" Klotho is safe and effective then, I don't think we should be worried. I mean, I can't speak for neuroscientists everywhere, but if some of us are willing to research how zapping the brains of healthy adults to improve memory and potentially improve cognitive function, then relatively speaking, I don't think researching the additive effects of a naturally occurring protein is a concern.

See the rest here:
The protein Klotho could extend the life of the brain. Is that a good thing? - Massive Science

Posted in Transhumanist | Comments Off on The protein Klotho could extend the life of the brain. Is that a good thing? – Massive Science

Opinion | Is big social media censoring those they disagree with? – The Breeze

Posted: October 12, 2020 at 8:06 am

Since late May, fact checks, censors, warnings and even removals have appeared on President Trumps social media posts. Throughout the pandemic, social media companies have been exposed for censoring all kinds of voices, like medical professionals, politicians, event organizers and even the president.

The problem many have with this censorship is that the majority of these voices appear to be conservative-leaning. Is it true that companies like Facebook, Twitter and YouTube are silencing those with opinions they dont agree with? Is big tech truly infringing upon the First Amendment and taking away individuals and the presidents right to free speech?

While this narrative has been effective in stirring the emotions of those who agree with the voices being censored, its most likely not the case.

The censorship, which began as far back as March, was introduced by most big social media companies as a method to combat dangerous misinformation regarding the pandemic.

Misinformation is one of the biggest problems related to the pandemic and has made an incredibly complicated issue even more so. Removing harmful, incorrect information from social media sounds like a great step to prevent dangerous underreaction or overaction on a large scale.

However, this was much easier said than done.

Almost immediately, people started to take issue with new censorship policies when posts on Facebook were mistakenly blocked by a bug in their anti-spam system. The blocked posts included sources many thought to be legitimate and well recognized like Buzzfeed and USA Today. The bug was soon corrected, but the conspiracy theories had just begun.

Fox News Tucker Carlson spoke about a viral video on TouTube by doctors who were suggesting that the COVID-19 death count was heavily inflated and that serious policy changes were necessary. The video was taken down by YouTube, and Carlsons main argument was that media giants were silencing any form of dissent from the opinions of those in power. This may sound like something to be seriously worried about, but its actually the exact kind of misinformation that threatens our safety.

The doctors statements, thought by many to be a credible source of information, have since been completely debunked and proved to be filled with a variety of statistical errors. YouTube was right to censor this information as it was false and had it been spread any further, it couldve persuaded the millions who saw it to take the pandemic much less seriously and act accordingly.

On May 26, 2020, Twitter placed the first fact check warning on one of Trumps tweets. The president and many of his supporters were outraged, as it seemed as though Twitter was participating in partisan bias and trying to silence Trump for a difference in political views.

However, when the information contained in the tweet and the surrounding situation is examined closely, it becomes clear why this censorship was justified and necessary for American safety. The tweet was an argument for the theory that mail-in ballots are completely untrustworthy and shouldnt be used in the upcoming election. The reason Trump made this argument wasnt that it was true, but because he knows his supporters are more likely than the opposition to disobey quarantine standards and come out in larger numbers for an in-person event, as they have been for months, to protest the quarantine laws.

The tweet was a political move filled with misinformation that could still put people in danger. This is exactly the kind of censorship that isnt done because of partisan bias, but because false information could put our national health in danger.

Shortly after Trumps tweet was censored, a federal appeals court rejected a lawsuit claiming that these social media agencies were suppressing conservative views.

Evan Holden is a sophomore political science major. Contact Evan at holdened@dukes.jmu.edu.

Read the original post:
Opinion | Is big social media censoring those they disagree with? - The Breeze

Posted in Censorship | Comments Off on Opinion | Is big social media censoring those they disagree with? – The Breeze

The New York Times Guild Once Again Demands Censorship Of Colleagues – The Intercept

Posted: at 8:06 am

The New York Times Guild, the union of employees of the Paper of Record, tweeted a condemnation on Sundayof one of their own colleagues, op-ed columnist Bret Stephens.Their denunciationwas marred by humiliating typos and even more so by creepy and authoritarian censorship demands and petulant appeals to management for enforcement of company rules against other journalists. To say that this is bizarre behavior from a union of journalists, of all people,is towoefullyunderstate the case.

What angered the union today was an op-ed by Stephens on Friday which voiced numerous criticisms of the Pulitzer-Prize-winning 1619 Project, published last year by the New York Times Magazine and spearheaded by reporter Nikole Hannah-Jones. One of the Projects principal arguments was expressed by a now-silently-deleted sentence that introduced it: that the countrys true birth date is not 1776, as has long been widely believed, but rather late 1619, when, the article claims, the first African slaves arrived on U.S. soil.

Despite its Pulitzer, the 1619 Project has become a hotly contested political and academic controversy, with the Trump administration seeking to block attempts to integrate its assertions into school curriculums,while numerousscholars of history accuse it of radically distorting historical fact, with some, such as Brown Universitys Glenn Loury, calling on the Pulitzer Board to revoke its award. Scholars have also vocally criticized the Times for stealth edits of the articleskey claims long afterpublication, without even noting to readers that it made these substantive changes let aloneexplaining why it made them.

In sum, the still-raging political, historical, and journalistic debate over the 1619 Project has become a majorcontroversy. In his Friday column, Stephens addressed the controversy by first noting the Projects positive contributions and accomplishments,then reviewed in detail the critiques of historians and other scholars of its central claims, and then sided with its critics by arguing that for all of its virtues, buzz, spinoffs and a Pulitzer Prize the 1619 Project has failed.

Without weighing in on the merits of Stephens critiques, some of which I agree with and some of which I do not, it is hardly debatable that his discussing thisvibrant multi-pronged debate issquarely within his functionas a political op-ed writer at a national newspaper. Stephens himself explained that he took the unusual step of critiquing his ownemployerswork because the 1619 Projecthas become, partly by its design and partly because of avoidable mistakes, a focal point of the kind of intense national debate that columnists are supposed to cover, contending that avoiding writing about it out of collegial deference is to be derelict in our responsibility to participate insocietys significant disputes.

But his colleagues in the New York Times Guildevidentlydo not believe that he had any right to express his views on these debates. Indeed, they are indignant that he did so. In a barely-literate tweet that not once buttwice misspelled the word its as its not a trivial level of ignorance for writers with the worlds most influential newspaper the union denounced Stephensand the paper itself on these grounds:

It is a short tweet, as tweets go, buttheyimpressively managed to pack it with multiple ironies, fallacies, and decreestypical of the petty tyrant. Above all else, thisstatement, and the mentality it reflects, is profoundly unjournalistic.

To start with, this is a case of journalists using their union not to demand greater editorial freedom or journalistic independence something one would reasonably expect from a journalists union but demanding its opposite: that writers at the New York Times be prohibited by management from expressing their views and perspectives about the controversies surrounding the 1619 Project.In other words: they are demanding that their own journalistic colleagues be silenced and censored. What kind of journalists plead with management for greater restrictions on journalistic expression rather than fewer?

Apparently, the answer is New York Times journalists. Indeed, this is not the first time they have publicly implored corporate management to restrict the freedom of expression and editorial freedom of their journalistic colleagues. At the end of July, the Guild issued a series of demands, one of which was that sensitivity reads should happen at the beginning of the publication process, with compensation for those who do them.

For those not familiar with sensitivity reads: consider yourself fortunate. As the New York Times itself reported in 2017, sensitivity readershave been used by book publishers to gut books that have been criticized, in order tovet the narrative for harmful stereotypes and suggested changes. The Guardian explained in 2018that sensitivity readers are a rapidly growing industry in the book publishing world to weed out any implicit bias or potentially objectionable material not just in storylines but even in characters. It quoted the author Lionel Shriver about the obvious dangers: there is, she said, a thin line between combing through manuscripts for anything potentially objectionable to particular subgroups and overt political censorship.

As creepy as sensitivity readers are for fiction writing and other publishing fields, it is indescribably toxic for journalism,which necessarily questions or pokes at rather than bows to the most cherished, sacred pieties. For it to be worthwhile, it must publish material reporting and opinion pieces thatmight be potentially objectionable to all sorts of powerful factions, including culturally hegemonic liberals.

But thisis a function which the New York Times Union wants not merely to avoid fulfilling themselves but, far worse, to deny their fellow journalists. They crave a whole new layer of editorial hoop-jumping in order to get published, a cumbersome, repressive new protocol for drawing even moreconstraining lines around what can and cannot be said beyond the restrictions already imposed by the standard orthodoxies of the Times and their tone-flattening editorial restrictions.

When journalists exploit their unions not to demand better pay, improved benefits, enhanced job security or greater journalistic independence but instead as an instrument for censoring their own journalistic colleagues, then the concept of unions and journalism is wildly perverted.

Then there is the tattletale petulance embedded in the Unions complaint. In demanding enforcement of workplace rules by management against a fellow journalist they do not specify which sacred rule Stephens allegedly violated these union members sound more like Human Resources Assistant Managers or workplace informants than they do intrepid journalists. Since when do unions of any kind, but especially unions of journalists, unite to complain that corporate managers and their editorial bosses have been too lax in the enforcement of rulesgoverning what their underlings can and cannot say?

The hypocrisy of the Unions grievance is almost too glaring to even bother highlighting, and is the least ofits sins. The union members denounce Stephens and the paper forgoing after one of its [sic] own and then, in the next breath, publicly vilify their colleagues column because, in their erudite view, it reeks. This is the same union whose members, just a few months ago, quite flamboyantly staged a multi-day social media protest a quite public one ina fit of rage becausethe papers Opinion Editor, James Bennet, published an op-ed by U.S. Senator Tom Cotton advocating the deployment of the U.S. military to repress protests and riots in U.S. cities; Bennet lost his job in the fallout. And many of these same union members now posturing as solemn, righteous opponents of publicly going after ones colleagues notoriously mocked, scorned, ridiculed, and condemned, first privately and then publicly, another colleague, Bari Weiss, until she left the paper, citing these incessant attacks.

Clearly this is not a union that dislikes public condemnations of colleagues. Whatever principle is motivating them, that is plainly not it.

Ive long been a harsh criticof Stephens (and Weiss) journalism and opinion writing. But it would never occur to me to take steps to try to silence them. If they were my colleagues and published an article I disliked or expressed views I found pernicious, I certainly would not whine to management that they broke the rules and insist that they should not have been allowed to have expressed what they believe.

Thats because Im a journalist, and I know that journalism can have value only if it fosters divergent views and seeks to expand rather thanreduce the freedom of discourse and expression permitted by society and by employers. And whatever one wants to say about Stephens career and record of writing and Ive had a lot of negative things to say about it harshly critiquingyour own employers Pulitzer-winning series, one beloved by powerful media, political and cultural figures, is thetypeof challenge to power that many journalists who do nothing but spout pleasing, popular pieties love to preen as embodying.

Therehas never been a media outlet where I have worked or where I have been published that did not frequently also publish opinions with which I disagree and articles I dislike, including the one in which I am currently writing. I would readily use my platforms to critique what was published, but it would never even occur to me take steps to try to prevent publication or, worse, issue pitiful public entreaties to management that Something Be Done. If youare eager to constrict the boundaries of expression, why would you choosejournalism of all lines of work? Itd be like someone whobelieves space travel to be an immoral wasteof resources opting to becomean astronaut for NASA.

Perhaps these tawdry episodes should be unsurprising. After all, one major reason that social media companies which never wanted the obligation tocensorbut instead sought to be content-neutral platforms for the transmission of communications in the mold of AT&T turned into active speech regulators was because the public, often led by journalists, began demanding that they censor more. Some journalists even devotesignificant chunks of their careerto publicly complaining thatFacebook and Twitterare failing to enforce their rules by not censoring robustly enough.

A belief in the virtues of free expression was once a cornerstone of the journalistic spirit. Guilds and unions fought against editorial control, notdemandedgreater amountsbe imposed by management. They defended colleagues when they were accused by editorial or corporatebosses of rules violations, not publicly tattled and invited, even advocated for, workplace disciplinary measures.

But a belief in free expression is being rapidly eclipsed in many societal sectors by a belief in the virtues of top-down managerial censorship, silencing and enhanced workplace punishment for thought and speech transgressions. As this imperious but whiny New York Times Guildcondemnationreflects, this trend can be seen most vividly, and most destructively, in mainstream American journalism. Nothing guts the core function of journalism more than this mindset.

Update: Oct. 11, 2020, 8:40p.m. ETThe New York Times Guild moments ago deleted its tweet denouncing Stephens and the paper, and thenposted this:

Original post:
The New York Times Guild Once Again Demands Censorship Of Colleagues - The Intercept

Posted in Censorship | Comments Off on The New York Times Guild Once Again Demands Censorship Of Colleagues – The Intercept

EFF and ACLU Ask Ninth Circuit to Overturn Government’s Censorship of Twitter’s Transparency Report – EFF

Posted: at 8:06 am

Citing national security concerns, the government is attempting to infringe on Twitter's First Amendment right to inform the public about secret government surveillance orders. For more than six years, Twitter has been fighting in court to share information about law enforcement orders it received in 2014. Now, Twitter has brought that fight to the Ninth Circuit Court of Appeals. EFF, along with the ACLU, filed an amicus brief last week to underscore the First Amendment rights at stake.

In 2014, Twitter submitted a draft transparency report to the FBI to review. The FBI censored the report, banning Twitter from sharing the total number of foreign intelligence surveillance orders the government had served within a six-month period. In response, Twitter filed suit in order to assert its First Amendment right to share that information.

Over half a decade of litigation later, the trial court judge resolved the case in April by dismissing Twitters First Amendment claim. Among the several concerning aspects of the opinion, the judge spent devoted only a single paragraph to analyzing Twitters First Amendment right to inform the public about law enforcement orders for its users information.

That single paragraph was not only perfunctory, but incorrect. The lower court failed to recognize one of the most basic rules underpinning the right to free speech in this country: the government must meet an extraordinarily exacting burden in order to censor speech before that speech occurs, which the Supreme Court has called the most serious and least tolerable infringement on First Amendment rights.

As we explained in our amicus brief, to pass constitutional scrutiny, the government must prove that silencing speech before it occurs is necessary to avoid harm that is not only extremely serious but is also imminent and irreparable. But the lower court judge concluded that censoring Twitters speech was acceptable without finding that any resulting harm to national security would be either imminent or irreparable. Nor did the judge address whether the censorship was actually necessary, and whether less-restrictive alternatives could mitigate the potential for harm.

This cursory analysis was a far cry from the extraordinarily exacting scrutiny that the First Amendment requires. We hope that the hope that the Ninth Circuit will say the same.

Go here to see the original:
EFF and ACLU Ask Ninth Circuit to Overturn Government's Censorship of Twitter's Transparency Report - EFF

Posted in Censorship | Comments Off on EFF and ACLU Ask Ninth Circuit to Overturn Government’s Censorship of Twitter’s Transparency Report – EFF

KSPP withdraws televised election address due to censorship by State-owned TV – Burma News International

Posted: at 8:06 am

KSPP withdraws televised election address due to censorship by State-owned TV

The Kachin State Peoples Party (KSPP) has become one more in a series of ethnic parties who have withdrawn from their election right to broadcast their policy statement on State-owned TV after censorship carried out by the Union Election Commission.U Naw Khu Na, Youth Secretary of the party explained The UEC delete our policy about the allocation of resources. The UEC wants the party to use the wording Both the Kachin people and citizens shall enjoy the States resources which would dilute the KSPPs policy the Kachin ethnics shall fully enjoy the States resources.The issue here is currently the National State and government controls all the resources of the ethnic states and most of the ethnic policies are campaigning for greater autonomy within a federal state and greater control over their natural resources.Last week the UEC censored about 50% of the election address of Tai-Leng (Shan-ni) Nationalities Development Party. The censored pieces covered weak points of the 1947 Constitution, youth development and dictatorship. The UEC has also interfered with the election address of the CNLD- The Chin National League for Democracy.

As The Kachin-based KSPP has designated the rights of people in Kachin State as the partys policy, and the KSPP does not want such censorship U Naw Khu Na continued The KSPP will broadcast it via its page. U Shwe Min, Chair of the Lisu National Development Party admitted: Some parties faced censorship but considered others did not encounter it. Our party was invited to Nay Pyi Taw for the recording of the election address. The party has directly sent it to the media due to the spread of COVID-19. The party planned to record it in Myanmar and Lisu languages. Due to the urgent condition, the party sent a Myanmar-language address only. The UEC did not censor the partys address.On September 20, Lisu National Development Partys election address was telecast. More than 50 political parties have presented their election addresses via the State-owned TVs. Lawow National Unity Party in Kachin State.The telecast of election addresses by the political parties via the State-owned MRTV channel has started since September.More than 90 political parties will compete in the 2020 General Election. Of them, more than 70 parties will contest in the whole country while the remaining parties will compete in the relevant regions and states, according to the statement by the Union Election Commission (UEC).

Follow this link:
KSPP withdraws televised election address due to censorship by State-owned TV - Burma News International

Posted in Censorship | Comments Off on KSPP withdraws televised election address due to censorship by State-owned TV – Burma News International

NFT and crypto art can magnify the truth of our reality without censorship – Cointelegraph

Posted: at 8:06 am

Earlier this month, Christies auction house announced the sale of a digital portrait of the Bitcoin code for more than $130,000 when the first estimated price was $12,000$18,000. It was the first time a nonfungible token was auctioned at one of the major auction houses for traditional art.

One of the last events, Bridge to Metaverse, presented by Snark.art, showed tokenized artworks by both established and emerging contemporary artists. A group exhibition brought leading artists of our time the Kabakovs, Kendell Geers, AES+F, Recycle Group and others to the blockchain space, and a series of panel discussions worked as a bridge between the traditional and blockchain-based art worlds with its own systems of distribution.

One criticism of the crypto art market has been the perceived naivety of the works. Although people were being distracted by the emergence of memes and CryptoKitties, there have also been some serious artists who have made their presence felt in the crypto world.

The traditional position of arts has been a commentary on the current state of affairs. A way to subversively criticize and, at the same time, to magnify the truth of what we are living through.

This is a perfect match with the emergence of the anonymity of blockchain technology in the new climate of being constantly tracked by our everyday gadgets.

Related: Painting a different picture: How digital artists use blockchain

Will the emerging artists in the new field of crypto art be influenced by traditional artists bringing their works into a shared blockchain space? With strong voices raising political, race, gender and inequality issues, their influx in these current times may create a shift in the way art is created, collected and viewed.

The traditional art market brings with it not only artists but also gallerists and curators who are naturally also drawn to growing markets. In fact, we are already seeing a move toward more classic ways of buying, with the Museum of Contemporary Art, Los Angeles purchasing works from artists to exhibit them in its own permanent collection.

Of course, this will also open the door to Crypto Art Basel, Biennale and other curated events whose crypto artworks will break sales records at Christies or Sothebys.

Fifty years from now, those first NFT artworks by world-acclaimed artists could become highly valuable, just like what happened with the first animations of John Whitney, the father of computer animation, who created the first animated art on his computer back in 1960.

Serious contemporary artists mirror and even magnify the truth of our reality without censorship. In the current political world, a marriage between the established artists and crypto art with no censorship is virtually a perfect match.

Misha Libman, co-founder of Snark.art, certainly believes this is a challenge to not only take on but to relish in, and he stated that:

Therefore, is the crypto art audience ready to be challenged with serious statements of shifting toward digitalization? Especially as established artists now find themselves with a new technological medium and a way to reach audiences they never had before.

The views, thoughts and opinions expressed here are the authors alone and do not necessarily reflect or represent the views and opinions of Cointelegraph.

Alexandra Luzan is a Ph.D. student researching the connection between new technologies and art at Ca Foscari University in Venice. For about a decade, Alexandra has been organizing tech conferences and other events in Europe dedicated to blockchain technology and artificial intelligence. She is equally interested in the relationship between blockchain tech and art.

Continue reading here:
NFT and crypto art can magnify the truth of our reality without censorship - Cointelegraph

Posted in Censorship | Comments Off on NFT and crypto art can magnify the truth of our reality without censorship – Cointelegraph

Page 1,182«..1020..1,1811,1821,1831,184..1,1901,200..»